TR 354 Mouse Pathology Tables
INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
DIMETHOXANE
NTP Experiment-Test: 05038-02 Report: PEIRPT03
Study Type: CHRONIC Date: 09/05/94
Route: GAVAGE Time: 09:04:25
Facility: Battelle Columbus Laboratory
Chemical CAS #: 828-00-2
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 7 5 9
Dead 7 9 7
Survivors
Terminal Sacrifice 36 35 34
Missing 1
Animals Examined Microscopically 50 49 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (44) (6) (45)
Cyst 1 (2%)
Intestine Large, Colon (48) (12) (48)
Parasite Metazoan 2 (4%)
Intestine Small, Duodenum (46) (8) (45)
Amyloid Deposition 1 (13%)
Intestine Small, Jejunum (48) (13) (45)
Hyperplasia, Lymphoid 1 (2%)
Liver (50) (19) (50)
Angiectasis 1 (2%)
Basophilic Focus 1 (2%)
Hematopoietic Cell Proliferation 11 (22%) 1 (5%) 11 (22%)
Hyperplasia, Lymphoid 1 (2%)
Infarct 1 (2%)
Inflammation, Chronic 3 (6%)
Inflammation, Necrotizing 2 (4%)
Leukocytosis 2 (4%) 2 (4%)
Necrosis, Coagulative 2 (4%) 1 (5%) 2 (4%)
Pigmentation, Hemosiderin 3 (6%)
Mesentery (41) (11) (49)
Inflammation, Chronic Active 4 (10%) 2 (18%) 2 (4%)
Necrosis, Coagulative 1 (2%)
Pancreas (49) (15) (49)
Cyst 1 (7%)
Hyperplasia, Lymphoid 1 (2%)
Inflammation, Suppurative 1 (2%)
Necrosis, Coagulative 1 (2%)
Acinus, Atrophy 3 (6%) 1 (7%) 1 (2%)
Salivary Glands (48) (13) (49)
Infiltration Cellular, Lymphocyte 1 (2%)
Stomach, Forestomach (49) (48) (48)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Acanthosis 5 (10%) 23 (48%)
Hyperkeratosis 4 (8%) 27 (56%)
Hyperplasia, Focal 3 (6%) 14 (29%) 22 (46%)
Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Inflammation, Chronic Active 4 (8%) 6 (13%)
Ulcer 1 (2%)
Stomach, Glandular (49) (12) (48)
Cyst 1 (2%) 4 (8%)
Inflammation, Chronic Active 1 (2%)
Epithelium, Hyperplasia 1 (2%)
Tooth (50) (14) (50)
Dysplasia 3 (6%)
Inflammation, Chronic Active 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (14) (50)
Cardiomyopathy, Chronic 1 (2%)
Fibrosis 1 (2%)
Inflammation, Chronic Active 1 (2%)
Necrosis, Fibrinoid 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (14) (50)
Accessory Adrenal Cortical Nodule 1 (2%)
Cyst 2 (4%)
Degeneration, Fatty 1 (2%) 1 (2%)
Hematopoietic Cell Proliferation 1 (2%)
Hypertrophy 2 (4%)
Necrosis, Coagulative 1 (7%)
Adrenal Gland, Medulla (49) (14) (50)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia 3 (6%) 1 (2%)
Islets, Pancreatic (49) (13) (49)
Hyperplasia 1 (2%)
Pituitary Gland (47) (19) (45)
Pars Distalis, Cyst 2 (4%)
Pars Distalis, Hyperplasia 14 (30%) 3 (16%) 18 (40%)
Thyroid Gland (50) (14) (47)
Follicle, Cyst 1 (7%) 1 (2%)
Follicular Cell, Hyperplasia 9 (18%) 2 (4%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49) (21) (50)
Atrophy 6 (12%) 2 (10%) 3 (6%)
Cyst 18 (37%) 9 (43%) 21 (42%)
Inflammation, Chronic Active 5 (10%) 1 (2%)
Mineralization 3 (6%) 1 (2%)
Uterus (50) (43) (50)
Angiectasis 1 (2%)
Bacterium 1 (2%)
Hemorrhage 1 (2%)
Inflammation, Suppurative 6 (12%) 4 (9%) 5 (10%)
Thrombosis 1 (2%)
Endometrium, Hyperplasia, Cystic, Glandular 40 (80%) 40 (93%) 45 (90%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (14) (50)
Femoral, Hyperplasia 4 (8%) 3 (6%)
Femoral, Myelofibrosis 2 (4%) 2 (4%)
Lymph Node (50) (16) (50)
Mediastinal, Hyperplasia, Lymphoid 1 (2%)
Mediastinal, Inflammation, Suppurative 1 (2%)
Mediastinal, Pigmentation, Hemosiderin 1 (2%)
Mesenteric, Angiectasis 1 (2%) 2 (13%)
Mesenteric, Cyst 1 (2%)
Mesenteric, Hematopoietic Cell Proliferation 1 (2%) 2 (13%)
Lymph Node, Mandibular (48) (13) (49)
Pigmentation, Hemosiderin 6 (13%) 4 (8%)
Spleen (50) (23) (50)
Hematopoietic Cell Proliferation 26 (52%) 6 (26%) 23 (46%)
Hyperplasia, Lymphoid 1 (2%) 3 (6%)
Necrosis, Coagulative 1 (2%)
Thymus (31) (9) (31)
Necrosis 1 (3%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (44) (10) (40)
Hyperplasia, Cystic 17 (39%) 28 (70%)
Skin (50) (14) (49)
Fibrosis 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (14) (50)
Joint, Tarsal, Metaplasia, Osseous 2 (4%)
Skeletal Muscle (50) (13) (50)
Fibrosis 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (14) (50)
Compression 1 (2%) 1 (2%)
Hydrocephalus 1 (2%)
Infiltration Cellular, Lymphocyte 1 (2%)
Inflammation, Suppurative 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (14) (50)
Edema 1 (7%)
Hyperplasia, Lymphoid 2 (4%)
Infiltration Cellular, Lymphocyte 2 (4%)
Inflammation, Chronic Active 1 (2%) 2 (4%)
Leukocytosis 1 (2%) 3 (6%)
Alveolar Epithelium, Hyperplasia 1 (7%) 1 (2%)
Nose (50) (14) (50)
Nasolacrimal Duct, Inflammation, Suppurative 2 (4%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1) (3)
Lens, Cataract 1 (33%)
Retina, Atrophy 1 (33%)
Harderian Gland (48) (11) (50)
Hyperplasia 3 (6%) 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (14) (50)
Cyst 1 (2%)
Glomerulosclerosis 1 (2%) 1 (7%) 1 (2%)
Hyperplasia, Lymphoid 1 (2%)
Infarct, Chronic 2 (4%)
Inflammation, Chronic Active 2 (4%)
Metaplasia, Osseous 1 (2%)
Mineralization 1 (2%)
Nephropathy, Chronic 4 (8%) 6 (12%)
Urinary Bladder (49) (12) (49)
Hyperplasia, Lymphoid 1 (2%)
Inflammation, Chronic Active 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 6 11 9
Dead 11 10 12
Survivors
Terminal Sacrifice 33 27 29
Wrong Sex 2
Animals Examined Microscopically 50 48 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (46) (15) (45)
Hyperplasia, Lymphoid 1 (2%)
Intestine Large, Colon (47) (19) (47)
Parasite Metazoan 1 (2%) 1 (5%) 2 (4%)
Intestine Large, Rectum (45) (16) (44)
Inflammation, Necrotizing 1 (2%)
Intestine Small, Duodenum (44) (18) (43)
Inflammation, Necrotizing 1 (6%) 1 (2%)
Intestine Small, Ileum (44) (16) (44)
Hyperplasia, Lymphoid 1 (2%)
Intestine Small, Jejunum (47) (19) (44)
Hyperplasia, Lymphoid 1 (2%)
Liver (49) (28) (50)
Cyst 1 (4%)
Degeneration, Fatty 1 (2%)
Hematopoietic Cell Proliferation 2 (4%) 8 (16%)
Hepatodiaphragmatic Nodule 1 (2%)
Infarct 1 (4%)
Inflammation, Chronic 1 (4%)
Inflammation, Necrotizing 2 (7%) 1 (2%)
Leukocytosis 2 (4%)
Necrosis, Coagulative 5 (10%) 4 (14%) 2 (4%)
Thrombosis 1 (4%)
Mesentery (41) (19) (48)
Inflammation, Chronic Active 1 (2%) 2 (4%)
Thrombosis 1 (2%)
Pancreas (48) (20) (49)
Cyst 1 (2%)
Inflammation, Chronic Active 1 (5%)
Acinus, Atrophy 1 (2%) 2 (10%) 2 (4%)
Acinus, Hyperplasia 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Duct, Ectasia 1 (2%)
Salivary Glands (49) (21) (50)
Inflammation, Chronic Active 1 (2%)
Stomach, Forestomach (47) (47) (50)
Acanthosis 4 (9%) 20 (40%)
Acanthosis, Focal 2 (4%)
Cyst 1 (2%)
Hyperkeratosis 1 (2%) 23 (46%)
Hyperkeratosis, Focal 1 (2%)
Hyperplasia, Focal 2 (4%) 7 (15%) 11 (22%)
Inflammation, Chronic Active 5 (10%)
Stomach, Glandular (47) (20) (50)
Cyst 1 (2%) 5 (10%)
Diverticulum 1 (2%)
Dysplasia 1 (2%)
Tooth (50) (20) (50)
Dysplasia 8 (16%) 1 (5%) 3 (6%)
Inflammation, Chronic Active 2 (4%) 6 (12%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (49) (21) (50)
Cardiomyopathy, Chronic 1 (2%)
Inflammation, Chronic Active 1 (5%)
Valve, Bacterium 1 (5%)
Valve, Inflammation, Chronic Active 1 (5%)
Valve, Thrombosis 1 (5%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (21) (50)
Accessory Adrenal Cortical Nodule 1 (2%)
Cyst 2 (4%)
Degeneration, Fatty 1 (2%)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia 1 (2%) 1 (2%)
Hypertrophy 3 (6%)
Adrenal Gland, Medulla (50) (21) (50)
Hyperplasia 5 (10%) 1 (5%) 4 (8%)
Islets, Pancreatic (48) (19) (49)
Hyperplasia 1 (2%)
Parathyroid Gland (41) (19) (45)
Cyst 3 (7%) 1 (2%)
Pituitary Gland (46) (20) (41)
Pars Distalis, Cyst 2 (4%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Thyroid Gland (49) (22) (50)
Follicle, Cyst 1 (2%) 1 (5%) 2 (4%)
Follicular Cell, Hyperplasia 7 (14%) 1 (5%) 3 (6%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (45) (20) (49)
Hyperplasia 1 (2%)
Penis (2) (4) (1)
Hemorrhage 1 (25%)
Preputial Gland (6) (6) (3)
Inflammation, Chronic Active 2 (33%) 1 (33%)
Duct, Dilatation 4 (67%) 2 (33%) 2 (67%)
Prostate (48) (21) (49)
Inflammation, Chronic Active 1 (5%) 3 (6%)
Seminal Vesicle (43) (20) (46)
Inflammation, Chronic Active 1 (5%) 1 (2%)
Testes (50) (21) (50)
Inflammation, Necrotizing 1 (2%)
Mineralization 1 (2%)
Germinal Epithelium, Degeneration 1 (5%)
Seminiferous Tubule, Atrophy 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (21) (50)
Femoral, Hyperplasia 5 (24%) 6 (12%)
Lymph Node (50) (24) (49)
Axillary, Hyperplasia, Plasma Cell 1 (4%) 1 (2%)
Inguinal, Hyperplasia, Plasma Cell 1 (4%)
Lumbar, Hyperplasia, Plasma Cell 1 (4%)
Mediastinal, Inflammation, Suppurative 1 (2%)
Mesenteric, Angiectasis 10 (20%) 6 (25%) 17 (35%)
Mesenteric, Cyst 1 (4%)
Mesenteric, Hematopoietic Cell Proliferation 12 (24%) 5 (21%) 17 (35%)
Mesenteric, Hyperplasia, Lymphoid 1 (2%)
Mesenteric, Thrombosis 1 (4%)
Lymph Node, Mandibular (48) (20) (49)
Hyperplasia, Lymphoid 1 (2%)
Hyperplasia, Plasma Cell 3 (6%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Inflammation, Chronic Active 1 (5%)
Pigmentation, Hemosiderin 2 (4%)
Spleen (49) (26) (50)
Hematopoietic Cell Proliferation 23 (47%) 10 (38%) 23 (46%)
Thymus (27) (12) (24)
Cyst 1 (4%) 2 (17%) 1 (4%)
Necrosis 1 (8%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (33) (49)
Alopecia 1 (2%) 3 (6%)
Fibrosis 3 (6%) 2 (4%)
Hyperkeratosis 1 (3%)
Inflammation, Chronic Active 9 (18%) 6 (18%) 8 (16%)
Metaplasia, Osseous 1 (3%)
Necrosis, Coagulative 1 (3%)
Parasite External 1 (2%) 3 (6%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (30) (50)
Joint, Femur, Tibia, Metaplasia, Osseous 1 (3%)
Joint, Tarsal, Metaplasia, Osseous 23 (46%) 15 (50%) 22 (44%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (49) (21) (50)
Compression 1 (5%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (49) (25) (50)
Edema, Acute 1 (2%)
Hemorrhage, Acute 1 (2%)
Inflammation, Chronic Active 2 (4%)
Leukocytosis 2 (8%) 1 (2%)
Thrombosis 1 (2%)
Alveolar Epithelium, Hyperplasia 6 (12%)
Nose (49) (21) (50)
Inflammation, Suppurative 1 (2%) 1 (5%)
Nasolacrimal Duct, Inflammation, Suppurative 2 (4%) 2 (10%) 2 (4%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 05038-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC DIMETHOXANE Date: 09/05/94
Route: GAVAGE Time: 09:04:25
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 250 MG/ 500 MG/
KG KG
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1) (1)
Atrophy 1 (100%)
Lens, Cataract 1 (100%)
Harderian Gland (48) (25) (48)
Hyperplasia 1 (2%) 1 (4%)
Inflammation, Chronic Active 1 (4%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (23) (50)
Cyst 1 (2%) 1 (2%)
Glomerulosclerosis 1 (2%)
Hydronephrosis 1 (2%) 5 (22%) 1 (2%)
Infarct 1 (2%) 1 (4%) 1 (2%)
Inflammation, Chronic Active 1 (4%)
Inflammation, Suppurative 1 (4%) 1 (2%)
Mineralization 2 (9%) 3 (6%)
Necrosis, Coagulative 1 (2%) 1 (2%)
Nephropathy, Chronic 27 (54%) 4 (17%) 24 (48%)
Artery, Necrosis, Fibrinoid 1 (4%)
Ureter (41) (21) (43)
Dilatation 1 (5%)
Urethra (23) (15) (29)
Inflammation, Suppurative 1 (7%)
Urinary Bladder (47) (21) (48)
Dilatation 5 (24%) 1 (2%)
Inflammation, Chronic Active 1 (5%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 70037-70037/70037
--multipart-boundary--